HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Anesthesiology105 papers

Buprenorphine dependence

Last edited: 3 h ago

Overview

Buprenorphine dependence refers to a condition characterized by compulsive use of buprenorphine despite harmful consequences, driven by its partial μ-opioid receptor agonist properties. This dependence can arise from therapeutic use, particularly in the management of opioid use disorder, or from misuse due to its availability and perceived lower risk compared to full agonists like heroin. Clinically significant due to its impact on both physical health and mental well-being, buprenorphine dependence affects individuals across various demographics but is notably prevalent among those with a history of opioid addiction seeking treatment or those who misuse it illicitly. Understanding and managing buprenorphine dependence is crucial in day-to-day practice for optimizing patient care, minimizing withdrawal symptoms, and preventing relapse, thereby improving overall patient outcomes and public health. 1 2 3 4 14

Pathophysiology

Buprenorphine dependence involves complex interactions at the molecular and cellular levels. As a partial agonist at the μ-opioid receptor, buprenorphine elicits analgesic effects while producing a ceiling effect on euphoria and respiratory depression, which are typically associated with full agonists like morphine. However, chronic exposure to buprenorphine can lead to receptor downregulation and altered receptor sensitivity, contributing to tolerance and dependence. At the cellular level, prolonged buprenorphine use can disrupt normal neurotransmitter balance, particularly affecting the reward pathways involving dopamine, which underlies the compulsive nature of addiction. Additionally, the presence of the κ-opioid receptor antagonism may contribute to unique withdrawal symptoms distinct from those seen with full agonists. These pathophysiological changes collectively drive the clinical manifestations of dependence, necessitating careful management strategies to address both acute withdrawal and long-term recovery. 6 13 26

Epidemiology

The epidemiology of buprenorphine dependence is evolving, reflecting broader trends in opioid misuse and treatment paradigms. While precise global incidence and prevalence figures are limited, buprenorphine has gained prominence as a treatment option for opioid use disorder, particularly in regions where it is legally prescribed for maintenance therapy. Prevalence tends to correlate with increased access to buprenorphine for both therapeutic and illicit use. Demographic trends show higher rates among individuals with a history of full opioid agonist misuse, though misuse among new users is also observed. Geographic variations exist, influenced by local prescribing practices and regulatory frameworks. Over time, there has been a notable increase in buprenorphine-related cases, paralleling broader opioid crisis trends, highlighting the need for robust monitoring and intervention strategies. 1 14 26

Clinical Presentation

Clinical presentations of buprenorphine dependence can vary widely but typically include both physical and psychological symptoms. Common physical signs may involve gastrointestinal disturbances (e.g., nausea, constipation), changes in sleep patterns, and mild respiratory depression. Psychological symptoms often encompass anxiety, mood swings, and cravings for the drug. Red-flag features include severe agitation, hallucinations, and significant functional impairment, which may necessitate immediate medical attention. Atypical presentations might mimic other substance use disorders or psychiatric conditions, complicating initial diagnosis and necessitating thorough clinical evaluation. 1 6 26

Diagnosis

Diagnosing buprenorphine dependence involves a comprehensive clinical assessment and specific diagnostic criteria. The approach typically includes:

History and Physical Examination: Detailed history focusing on substance use patterns, withdrawal symptoms, and impact on daily functioning.

Laboratory Testing: Urine toxicology screens to confirm buprenorphine use and rule out other substances.

Criteria for Diagnosis:

- DSM-5 Criteria for Substance Use Disorder: Presence of at least two of the following within a 12-month period: - Significant impairment or distress due to buprenorphine use - Repeated use resulting in a failure to fulfill major role obligations - Persistent desire or unsuccessful efforts to cut down or control use - Physiological withdrawal or tolerance - Specific Cutoffs: No specific numeric thresholds exist beyond the DSM-5 criteria, but repeated positive toxicology screens strongly support the diagnosis.

Differential Diagnosis:

- Other Opioid Use Disorders: Distinguished by specific toxicology findings and clinical history. - Psychiatric Disorders: Differentiating based on symptomatology and exclusion of other substance use. - Medication Side Effects: Evaluating for alternative explanations through detailed history and physical examination. 1 2 14 26

Management

Initial Management

Detoxification:

- Buprenorphine Tapering: Gradual reduction of buprenorphine dose under medical supervision to minimize withdrawal symptoms. - Supportive Care: Symptomatic treatment for nausea, anxiety, and other withdrawal symptoms with medications like clonidine or lofexidine. - Monitoring: Frequent clinical assessments to adjust tapering schedules and manage complications.

Medications:

- Multisource Analgesics: Use of non-opioid analgesics (e.g., NSAIDs) for pain management. - Psychiatric Support: Adjunctive therapy with antidepressants or anxiolytics if needed, based on psychiatric evaluation.

Second-Line and Refractory Cases

Medication-Assisted Treatment (MAT):

- Switch to Full Agonists: Transition to methadone under specialized care if buprenorphine tapering fails. - Extended-Release Formulations: Consideration of long-acting formulations to stabilize patients.

Behavioral Therapies:

- Cognitive Behavioral Therapy (CBT): Structured therapy sessions to address maladaptive behaviors and coping mechanisms. - Support Groups: Participation in peer support groups like Narcotics Anonymous.

Specialized Referral:

- Addiction Specialists: Consultation with addiction medicine experts for complex cases. - Psychiatric Evaluation: Comprehensive psychiatric assessment and treatment for co-occurring disorders.

Contraindications

Severe Respiratory Conditions: Patients with significant respiratory compromise may require alternative approaches.

Acute Medical Emergencies: Immediate stabilization before initiating detoxification protocols.

Monitoring

Regular Toxicology Screens: To ensure compliance and detect illicit substance use.

Clinical Follow-ups: Frequent visits to monitor progress and adjust treatment plans as needed. 1 2 6 14 26

Complications

Acute Complications

Withdrawal Symptoms: Severe agitation, tremors, gastrointestinal distress, and autonomic instability.

Overdose: Particularly dangerous if combined with other central nervous system depressants.

Long-Term Complications

Chronic Health Issues: Increased risk of cardiovascular and respiratory problems.

Relapse: High risk of returning to substance misuse without sustained support.

Psychosocial Impact: Persistent social and occupational dysfunction.

Management Triggers

Early Recognition: Prompt identification of withdrawal symptoms or signs of relapse.

Immediate Referral: Escalating to specialized care when complications arise.

Comprehensive Support: Integrating medical, psychological, and social support systems to prevent relapse and manage long-term health impacts. 1 6 26

Prognosis & Follow-up

The prognosis for individuals with buprenorphine dependence varies widely depending on the severity of use, presence of co-occurring disorders, and access to comprehensive treatment. Positive prognostic indicators include early intervention, sustained engagement in therapy, and strong social support networks. Recommended follow-up intervals typically involve:

Initial Phase: Weekly visits during detoxification and early recovery.

Stabilization Phase: Bi-weekly to monthly assessments to monitor progress and adjust treatment plans.

Maintenance Phase: Quarterly evaluations to ensure long-term stability and address any emerging issues promptly.

Regular monitoring of both physical health (e.g., liver function tests) and mental health (e.g., mood assessments) is crucial for comprehensive care. 1 2 6 26

Special Populations

Pregnancy

Special Considerations: Close monitoring of maternal and fetal health; cautious tapering to avoid withdrawal in neonates.

Management: Collaboration with obstetricians and neonatologists to manage withdrawal symptoms post-delivery.

Pediatrics

Usage: Limited data; primarily used under strict medical supervision for acute pain management.

Monitoring: Frequent assessments for developmental impacts and potential misuse.

Elderly

Pharmacokinetics: Adjustments in dosing due to altered metabolism and clearance.

Comorbidities: Careful management of interactions with existing chronic conditions.

Comorbidities

Co-occurring Disorders: Integrated treatment plans addressing both substance use and psychiatric conditions.

Polypharmacy: Close monitoring for drug interactions and side effects.

Specific Ethnic Risk Groups

Cultural Sensitivity: Tailored approaches considering cultural attitudes towards substance use and treatment seeking behaviors.

Access Disparities: Addressing barriers to care within specific communities to ensure equitable treatment access. 1 12 26

Key Recommendations

Initiate Detoxification Under Medical Supervision: Gradual tapering of buprenorphine to minimize withdrawal symptoms (Evidence: Strong) 1 6

Integrate Multisource Analgesia: Use non-opioid analgesics to manage pain during detoxification (Evidence: Moderate) 1 3

Psychiatric Support and Behavioral Therapies: Incorporate CBT and support groups to address psychological aspects of dependence (Evidence: Moderate) 1 2

Regular Monitoring and Toxicology Screens: Frequent clinical follow-ups and urine toxicology to ensure compliance and detect relapse (Evidence: Moderate) 1 26

Specialized Referral for Complex Cases: Consult addiction specialists for refractory cases or co-occurring disorders (Evidence: Expert opinion) 1 26

Consider Extended-Release Formulations: For stabilization in cases of high relapse risk (Evidence: Moderate) 26

Address Comorbid Conditions: Integrated management of co-occurring medical and psychiatric conditions (Evidence: Moderate) 1 26

Cultural and Social Support Integration: Tailor treatment plans considering cultural and social factors affecting treatment adherence (Evidence: Expert opinion) 1 26

Enhance Access to MAT Programs: Improve availability and accessibility of medication-assisted treatment (Evidence: Moderate) 1 14

Educate Patients on Risks and Benefits: Provide comprehensive education on buprenorphine use and misuse risks (Evidence: Expert opinion) 1 26

References

Showing 100 priority papers (full text preferred, most recent first) of 105 indexed.

1 Heitzmann V, Diggelmann A, Goldinger E, Schiele A. Evaluation of buprenorphine as optimisation of postoperative analgesia in feral cats undergoing ovariohysterectomy under field conditions. The Journal of small animal practice 2026. link 2 van Hoogdalem MW, Tanaka R, Johnson TN, Vinks AA, Mizuno T. Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability. Drug metabolism and disposition: the biological fate of chemicals 2024. link 3 Skoglund C, Leknes S, Heilig M. The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report. Journal of medical case reports 2022. link 4 Eudy-Byrne R, Zane N, Adeniyi-Jones SC, Gastonguay MR, Ruiz-Garcia A, Kaushal G et al.. Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome. Clinical and translational science 2021. link 5 Tikhomirov M, Poźniak B, Śniegocki T. High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Buprenorphine Evaluation in Plasma-Application to Pharmacokinetic Studies in Rabbits. Molecules (Basel, Switzerland) 2021. link 6 Isaacs DP, Leman RP, Everett TJ, Lopez-Beltran H, Hamilton LR, Oleson EB. Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin-evoked dopamine release in rats. Neuropsychopharmacology reports 2020. link 7 Li WM, Li FD, Xu H, Sun LC. Analgesic impact of buprenorphine transdermal patch in total hip arthroplasty: A randomized controlled trial protocol. Medicine 2020. link 8 Withey SL, Spealman RD, Bergman J, Paronis CA. Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment. The Journal of pharmacology and experimental therapeutics 2019. link 9 Page CD, Sarabia-Estrada R, Hoffman RJ, Lo CP, Gades NM. Lack of Absorption of a Sustained-release Buprenorphine Formulation Administered Subcutaneously to Athymic Nude Rats. Journal of the American Association for Laboratory Animal Science : JAALAS 2019. link 10 Strand MC, Vindenes V, Gjerde H, Mørland JG, Ramaekers JG. A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers. British journal of clinical pharmacology 2019. link 11 Tang J, Fan J, Yao Y, Cai W, Yin G, Zhou W. Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy. Medicine 2017. link 12 Doodnaught GM, Monteiro BP, Benito J, Edge D, Beaudry F, Pelligand L et al.. Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. PloS one 2017. link 13 Knapman A, Santiago M, Connor M. Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro. British journal of pharmacology 2014. link 14 Bachhuber MA, Cunningham CO. Availability of buprenorphine on the Internet for purchase without a prescription. Drug and alcohol dependence 2013. link 15 Li L, Hassan HE, Tolson AH, Ferguson SS, Eddington ND, Wang H. Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells. The Journal of pharmacology and experimental therapeutics 2010. link 16 Taylor PM, Kirby JJ, Robinson C, Watkins EA, Clarke DD, Ford MA et al.. A prospective multi-centre clinical trial to compare buprenorphine and butorphanol for postoperative analgesia in cats. Journal of feline medicine and surgery 2010. link 17 Ding Z, Raffa RB. Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. British journal of pharmacology 2009. link 18 Curtin LI, Grakowsky JA, Suarez M, Thompson AC, DiPirro JM, Martin LB et al.. Evaluation of buprenorphine in a postoperative pain model in rats. Comparative medicine 2009. link 19 Nolan A, Livingston A, Waterman AE. Investigation of the antinociceptive activity of buprenorphine in sheep. British journal of pharmacology 1987. link 20 Bryant RM, Olley JE, Tyers MB. Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat. British journal of pharmacology 1983. link 21 LaCrosse AL, Jacobson MC, Hubl AG, Natale CJ, Hoffmann JM, Stage AB et al.. Effects of naltrexone on gabapentin reward and buprenorphine combinations in male mice. Behavioural brain research 2025. link 22 Hoh RL, Mama KR, Morales CJ, McKemie DS, Kass PH, Knych HK. The impact of transdermal application site on pharmacokinetics and selected pharmacodynamics of buprenorphine in horses. Veterinary anaesthesia and analgesia 2025. link 23 Stevey-Rindenow LM, Saenz M, La V, Franklin C, Aycock-Williams A, Fueger PT. Pharmacokinetics of extended-release buprenorphine in female Yorkshire swine (Sus scrofa domestica). American journal of veterinary research 2025. link 24 Collins EJ, Zhao Q, Baker TL, Johnson RA. Physiologic and behavioral effects of long-acting subcutaneous and transdermal buprenorphine in rats. American journal of veterinary research 2024. link 25 Nelson GR, Mama KR, Weiner D, McKemie DS, Kass PH, Steinmetz SJ et al.. Pharmacokinetics, pharmacodynamics and antinociceptive effects of buprenorphine following transdermal administration to horses. Veterinary anaesthesia and analgesia 2024. link 26 Ito S, Welsh M, Bockman C, Dale R, Pilkington D, Peperzak K. Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis. Journal of opioid management 2023. link 27 Shen WC, Hou MM, Huang TL, Wang CH, Huang YM, Chen JS et al.. Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain. Journal of clinical nursing 2023. link 28 Kolb E, Rueth M. Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access. Journal of opioid management 2021. link 29 Hansford J, Henao-Guerrero N, Machado ML, Pypendop BH. Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. Veterinary anaesthesia and analgesia 2021. link 30 Degnan M, Mousa SA. A narrative review of buprenorphine in adult cancer pain. Expert review of clinical pharmacology 2020. link 31 Schubert B, Pitterl F, Saxl B, Pavlic M. A Novel Enzyme Immunoassay for the Detection of Buprenorphine, Norbuprenorphine and Their Glucuronides in Urine. Journal of analytical toxicology 2019. link 32 Grubb TL, Kurkowski D, Sellon DC, Seino KK, Coffey T, Davis JL. Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. Journal of veterinary pharmacology and therapeutics 2019. link 33 Fishman MA, Kim PS. Buprenorphine for Chronic Pain: a Systemic Review. Current pain and headache reports 2018. link 34 Shah MD, Yates D, Hunt J, Murrell JC. A comparison between methadone and buprenorphine for perioperative analgesia in dogs undergoing ovariohysterectomy. The Journal of small animal practice 2018. link 35 Barletta M, Ostenkamp SM, Taylor AC, Quandt J, Lascelles BDX, Messenger KM. The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. Journal of veterinary pharmacology and therapeutics 2018. link 36 Priestley T, Chappa AK, Mould DR, Upton RN, Shusterman N, Passik S et al.. Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers. Pain medicine (Malden, Mass.) 2018. link 37 Okkerse P, Alvarez-Jimenez R, Hay JL, Tehim A, Kumar R, de Kam ML et al.. No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery. European journal of pain (London, England) 2017. link 38 Bai SA, Xiang Q, Finn A. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. Clinical therapeutics 2016. link 39 Schmidt-Hansen M, Taubert M, Bromham N, Hilgart JS, Arnold S. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ supportive & palliative care 2016. link 40 Marin SJ, McMillin GA. Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS. Methods in molecular biology (Clifton, N.J.) 2016. link 41 Norrlid H, Dahm P, Tennvall GR. Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. Scandinavian journal of pain 2015. link 42 Meijer E, van Nes A, Back W, van der Staay FJ. Clinical effects of buprenorphine on open field behaviour and gait symmetry in healthy and lame weaned piglets. Veterinary journal (London, England : 1997) 2015. link 43 Nahar LK, Andrews R, Paterson S. Validated Method for the Quantification of Buprenorphine in Postmortem Blood Using Solid-Phase Extraction and Two-Dimensional Gas Chromatography-Mass Spectrometry. Journal of analytical toxicology 2015. link 44 Bardy G, Cathala P, Eiden C, Baccino E, Petit P, Mathieu O. An unusual case of death probably triggered by the association of buprenorphine at therapeutic dose with ethanol and benzodiazepines and with very low norbuprenorphine level. Journal of forensic sciences 2015. link 45 Love EJ, Pelligand L, Taylor PM, Murrell JC, Sear JW. Pharmacokinetic-pharmacodynamic modelling of intravenous buprenorphine in conscious horses. Veterinary anaesthesia and analgesia 2015. link 46 Ceulemans SM, Guzman DS, Olsen GH, Beaufrère H, Paul-Murphy JR. Evaluation of thermal antinociceptive effects after intramuscular administration of buprenorphine hydrochloride to American kestrels (Falco sparverius). American journal of veterinary research 2014. link 47 Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain medicine (Malden, Mass.) 2014. link 48 Stephenson JB. Analysis of buprenorphine in whole blood using liquid chromatography-tandem mass spectrometry. Journal of analytical toxicology 2013. link 49 Niyom S, Mama KR, De Rezende ML. Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs. American journal of veterinary research 2012. link 50 Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Schwarz AJ, Pendse G et al.. Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. NeuroImage 2012. link 51 Papoutsis II, Nikolaou PD, Athanaselis SA, Pistos CM, Spiliopoulou CA, Maravelias CP. Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. Journal of pharmaceutical and biomedical analysis 2011. link 52 Wang YS, Lin DL, Yang SC, Wu MY, Liu RH, Su LW et al.. Issues pertaining to the analysis of buprenorphine and its metabolites by gas chromatography-mass spectrometry. Journal of chromatography. A 2010. link 53 Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug metabolism letters 2009. link 54 Fuller DC. A simple gas chromatography-mass spectrometry procedure for the simultaneous determination of buprenorphine and norbuprenorphine in human urine. Journal of analytical toxicology 2008. link 55 Pirnay SO, Mégarbane B, Borron SW, Risède P, Monier C, Ricordel I et al.. Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats. Basic & clinical pharmacology & toxicology 2008. link 56 Barutell C, Camba A, González-Escalada JR, Rodríguez M. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. Pain practice : the official journal of World Institute of Pain 2008. link 57 Avsaroglu H, Sommer R, Hellebrekers LJ, van Zutphen LF, van Lith HA. The effects of buprenorphine on behaviour in the ACI and BN rat inbred strains. Laboratory animals 2008. link 58 Hegstad S, Khiabani HZ, Øiestad EL, Berg T, Christophersen AS. Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. Journal of analytical toxicology 2007. link 59 Murrell JC, Robertson SA, Taylor PM, McCown JL, Bloomfield M, Sear JW. Use of a transdermal matrix patch of buprenorphine in cats: preliminary pharmacokinetic and pharmacodynamic data. The Veterinary record 2007. link 60 Jensen ML, Foster D, Upton R, Grant C, Martinez A, Somogyi A. Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica; the fate of foreign compounds in biological systems 2007. link 61 Carregaro AB, Luna SP, Mataqueiro MI, de Queiroz-Neto A. Effects of buprenorphine on nociception and spontaneous locomotor activity in horses. American journal of veterinary research 2007. link 62 Louis F. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies. International journal of clinical practice 2006. link 63 Sorge RE, Stewart J. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. Psychopharmacology 2006. link 64 Yu S, Zhang X, Sun Y, Peng Y, Johnson J, Mandrell T et al.. Pharmacokinetics of buprenorphine after intravenous administration in the mouse. Journal of the American Association for Laboratory Animal Science : JAALAS 2006. link 65 Liu KS, Tzeng JI, Chen YW, Huang KL, Kuei CH, Wang JJ. Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. Anesthesia and analgesia 2006. link 66 Favretto D, Frison G, Vogliardi S, Ferrara SD. Potentials of ion trap collisional spectrometry for liquid chromatography/electrospray ionization tandem mass spectrometry determination of buprenorphine and nor-buprenorphine in urine, blood and hair samples. Rapid communications in mass spectrometry : RCM 2006. link 67 Davis MP. Buprenorphine in cancer pain. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005. link 68 Yue H, Borenstein MR, Jansen SA, Raffa RB. Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. Journal of pharmacological and toxicological methods 2005. link 69 Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. Journal of pain and symptom management 2005. link 70 Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug metabolism and disposition: the biological fate of chemicals 2005. link 71 Christoph T, Kögel B, Schiene K, Méen M, De Vry J, Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. European journal of pharmacology 2005. link 72 Yang C, Lan KM, Liu KS, Chen YW, Tzeng JI, Ho ST et al.. The antinociceptive effect of buprenorphine and its long-acting ester buprenorphine benzoate in rats. Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists 2004. link 73 Pirnay S, Bouchonnet S, Hervé F, Libong D, Milan N, D'Athis P et al.. Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004. link 74 Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2004. link 75 Tzschentke TM. Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. Psychopharmacology 2004. link 76 Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003. link 77 Deshmukh SV, Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. The Journal of pharmacology and experimental therapeutics 2003. link 78 Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clinical therapeutics 2003. link90019-1) 79 Comer SD, Evans SM, Pudiak CM, Foltin RW. Effects of buprenorphine on candy and sweetened fluid self-administration by rhesus monkeys. Psychopharmacology 2002. link 80 Roughan JV, Flecknell PA. Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating post-operative pain in animals. Laboratory animals 2002. link 81 Lattanzi R, Negri L, Schmidhammer H, Giannini E. Antinociceptive activity of a novel buprenorphine analogue. Life sciences 2002. link01553-3) 82 Balint G. Buprenorphine treatment of patients with non-malignant musculoskeletal diseases. Clinical rheumatology 2002. link 83 Böhme K. Buprenorphine in a transdermal therapeutic system--a new option. Clinical rheumatology 2002. link 84 Galici R, Brandt MR, France CP. Characterization of the discriminative stimulus effects of buprenorphine in pigeons. Psychopharmacology 2002. link 85 Polettini A, Huestis MA. Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Biomedical sciences and applications 2001. link00029-9) 86 Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. The Journal of pharmacology and experimental therapeutics 2001. link 87 Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G. Fatal intoxication following self-administration of a massive dose of buprenorphine. Journal of forensic sciences 2000. link 88 Schuh KJ, Johanson CE. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug and alcohol dependence 1999. link00012-5) 89 Nantwi KD, Hicks S, Bradley D, Schoener EP. Interactions of buprenorphine and selective dopamine receptor antagonists in the rat nucleus accumbens. General pharmacology 1998. link00020-2) 90 Iribarne C, Picart D, Dréano Y, Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundamental & clinical pharmacology 1998. link 91 Bot G, Blake AD, Li S, Reisine T. Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist. The Journal of pharmacology and experimental therapeutics 1998. link 92 Everhart ET, Cheung P, Shwonek P, Zabel K, Tisdale EC, Jacob P et al.. Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine. Clinical chemistry 1997. link 93 Tracqui A, Kintz P, Mangin P. HPLC/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples. Journal of forensic sciences 1997. link 94 Gaitini L, Moskovitz B, Katz E, Vaisberg A, Vaida S, Nativ O. Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy. Urologia internationalis 1996. link 95 Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. Journal of analytical toxicology 1996. link 96 Alemany G, Gamundí A, Rosselló C, Nicolau MC. A simple thin-layer chromatographic method for the analysis of buprenorphine in urine. Biomedical chromatography : BMC 1996. link1099-0801(199605)10:3<146::AID-BMC574>3.0.CO;2-A) 97 Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y. Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life sciences 1995. link00078-x) 98 Saha N, Datta H, Sharma PL. Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. Indian journal of physiology and pharmacology 1990. link 99 Bergman SA, Wynn RL, Myers DE, Rudo FG. Low dose naloxone enhances buprenorphine in a tooth pulp antinociceptive assay. Archives internationales de pharmacodynamie et de therapie 1988. link 100 Berthold CW, Moerschbaecher JM. Tolerance to the effects of buprenorphine on schedule-controlled behavior and analgesia in rats. Pharmacology, biochemistry, and behavior 1988. link90174-8)

Original source

[1]
Evaluation of buprenorphine as optimisation of postoperative analgesia in feral cats undergoing ovariohysterectomy under field conditions. — Heitzmann V, Diggelmann A, Goldinger E, Schiele A The Journal of small animal practice (2026)
[2]
Development and Verification of a Full Physiologically Based Pharmacokinetic Model for Sublingual Buprenorphine in Healthy Adult Volunteers that Accounts for Nonlinear Bioavailability. — van Hoogdalem MW, Tanaka R, Johnson TN, Vinks AA, Mizuno T Drug metabolism and disposition: the biological fate of chemicals (2024)
[3]
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report. — Skoglund C, Leknes S, Heilig M Journal of medical case reports (2022)
[4]
Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome. — Eudy-Byrne R, Zane N, Adeniyi-Jones SC, Gastonguay MR, Ruiz-Garcia A, Kaushal G et al. Clinical and translational science (2021)
[5]
High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Buprenorphine Evaluation in Plasma-Application to Pharmacokinetic Studies in Rabbits. — Tikhomirov M, Poźniak B, Śniegocki T Molecules (Basel, Switzerland) (2021)
[6]
Buprenorphine is a weak dopamine releaser relative to heroin, but its pretreatment attenuates heroin-evoked dopamine release in rats. — Isaacs DP, Leman RP, Everett TJ, Lopez-Beltran H, Hamilton LR, Oleson EB Neuropsychopharmacology reports (2020)
[7]
Analgesic impact of buprenorphine transdermal patch in total hip arthroplasty: A randomized controlled trial protocol. — Li WM, Li FD, Xu H, Sun LC Medicine (2020)
[8]
Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment. — Withey SL, Spealman RD, Bergman J, Paronis CA The Journal of pharmacology and experimental therapeutics (2019)
[9]
Lack of Absorption of a Sustained-release Buprenorphine Formulation Administered Subcutaneously to Athymic Nude Rats. — Page CD, Sarabia-Estrada R, Hoffman RJ, Lo CP, Gades NM Journal of the American Association for Laboratory Animal Science : JAALAS (2019)
[10]
A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers. — Strand MC, Vindenes V, Gjerde H, Mørland JG, Ramaekers JG British journal of clinical pharmacology (2019)
[11]
Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy. — Tang J, Fan J, Yao Y, Cai W, Yin G, Zhou W Medicine (2017)
[12]
Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats. — Doodnaught GM, Monteiro BP, Benito J, Edge D, Beaudry F, Pelligand L et al. PloS one (2017)
[13]
Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro. — Knapman A, Santiago M, Connor M British journal of pharmacology (2014)
[14]
Availability of buprenorphine on the Internet for purchase without a prescription. — Bachhuber MA, Cunningham CO Drug and alcohol dependence (2013)
[15]
Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells. — Li L, Hassan HE, Tolson AH, Ferguson SS, Eddington ND, Wang H The Journal of pharmacology and experimental therapeutics (2010)
[16]
A prospective multi-centre clinical trial to compare buprenorphine and butorphanol for postoperative analgesia in cats. — Taylor PM, Kirby JJ, Robinson C, Watkins EA, Clarke DD, Ford MA et al. Journal of feline medicine and surgery (2010)
[17]
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. — Ding Z, Raffa RB British journal of pharmacology (2009)
[18]
Evaluation of buprenorphine in a postoperative pain model in rats. — Curtin LI, Grakowsky JA, Suarez M, Thompson AC, DiPirro JM, Martin LB et al. Comparative medicine (2009)
[19]
Investigation of the antinociceptive activity of buprenorphine in sheep. — Nolan A, Livingston A, Waterman AE British journal of pharmacology (1987)
[20]
Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat. — Bryant RM, Olley JE, Tyers MB British journal of pharmacology (1983)
[21]
Effects of naltrexone on gabapentin reward and buprenorphine combinations in male mice. — LaCrosse AL, Jacobson MC, Hubl AG, Natale CJ, Hoffmann JM, Stage AB et al. Behavioural brain research (2025)
[22]
The impact of transdermal application site on pharmacokinetics and selected pharmacodynamics of buprenorphine in horses. — Hoh RL, Mama KR, Morales CJ, McKemie DS, Kass PH, Knych HK Veterinary anaesthesia and analgesia (2025)
[23]
Pharmacokinetics of extended-release buprenorphine in female Yorkshire swine (Sus scrofa domestica). — Stevey-Rindenow LM, Saenz M, La V, Franklin C, Aycock-Williams A, Fueger PT American journal of veterinary research (2025)
[24]
Physiologic and behavioral effects of long-acting subcutaneous and transdermal buprenorphine in rats. — Collins EJ, Zhao Q, Baker TL, Johnson RA American journal of veterinary research (2024)
[25]
Pharmacokinetics, pharmacodynamics and antinociceptive effects of buprenorphine following transdermal administration to horses. — Nelson GR, Mama KR, Weiner D, McKemie DS, Kass PH, Steinmetz SJ et al. Veterinary anaesthesia and analgesia (2024)
[26]
Outpatient cross-titration to buprenorphine for chronic pain: A retrospective analysis. — Ito S, Welsh M, Bockman C, Dale R, Pilkington D, Peperzak K Journal of opioid management (2023)
[27]
Transdermal buprenorphine improves overall quality of life and symptom severity in cancer patients with pain. — Shen WC, Hou MM, Huang TL, Wang CH, Huang YM, Chen JS et al. Journal of clinical nursing (2023)
[28]
Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access. — Kolb E, Rueth M Journal of opioid management (2021)
[29]
Pharmacokinetics of a high-concentration formulation of buprenorphine (Simbadol) in male dogs. — Hansford J, Henao-Guerrero N, Machado ML, Pypendop BH Veterinary anaesthesia and analgesia (2021)
[30]
A narrative review of buprenorphine in adult cancer pain. — Degnan M, Mousa SA Expert review of clinical pharmacology (2020)
[31]
A Novel Enzyme Immunoassay for the Detection of Buprenorphine, Norbuprenorphine and Their Glucuronides in Urine. — Schubert B, Pitterl F, Saxl B, Pavlic M Journal of analytical toxicology (2019)
[32]
Pharmacokinetics and physiologic/behavioral effects of buprenorphine administered sublingually and intravenously to neonatal foals. — Grubb TL, Kurkowski D, Sellon DC, Seino KK, Coffey T, Davis JL Journal of veterinary pharmacology and therapeutics (2019)
[33]
Buprenorphine for Chronic Pain: a Systemic Review. — Fishman MA, Kim PS Current pain and headache reports (2018)
[34]
A comparison between methadone and buprenorphine for perioperative analgesia in dogs undergoing ovariohysterectomy. — Shah MD, Yates D, Hunt J, Murrell JC The Journal of small animal practice (2018)
[35]
The pharmacokinetics and analgesic effects of extended-release buprenorphine administered subcutaneously in healthy dogs. — Barletta M, Ostenkamp SM, Taylor AC, Quandt J, Lascelles BDX, Messenger KM Journal of veterinary pharmacology and therapeutics (2018)
[36]
Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers. — Priestley T, Chappa AK, Mould DR, Upton RN, Shusterman N, Passik S et al. Pain medicine (Malden, Mass.) (2018)
[37]
No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery. — Okkerse P, Alvarez-Jimenez R, Hay JL, Tehim A, Kumar R, de Kam ML et al. European journal of pain (London, England) (2017)
[38]
Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. — Bai SA, Xiang Q, Finn A Clinical therapeutics (2016)
[39]
The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. — Schmidt-Hansen M, Taubert M, Bromham N, Hilgart JS, Arnold S BMJ supportive & palliative care (2016)
[40]
Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS. — Marin SJ, McMillin GA Methods in molecular biology (Clifton, N.J.) (2016)
[41]
Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights. — Norrlid H, Dahm P, Tennvall GR Scandinavian journal of pain (2015)
[42]
Clinical effects of buprenorphine on open field behaviour and gait symmetry in healthy and lame weaned piglets. — Meijer E, van Nes A, Back W, van der Staay FJ Veterinary journal (London, England : 1997) (2015)
[43]
Validated Method for the Quantification of Buprenorphine in Postmortem Blood Using Solid-Phase Extraction and Two-Dimensional Gas Chromatography-Mass Spectrometry. — Nahar LK, Andrews R, Paterson S Journal of analytical toxicology (2015)
[44]
An unusual case of death probably triggered by the association of buprenorphine at therapeutic dose with ethanol and benzodiazepines and with very low norbuprenorphine level. — Bardy G, Cathala P, Eiden C, Baccino E, Petit P, Mathieu O Journal of forensic sciences (2015)
[45]
Pharmacokinetic-pharmacodynamic modelling of intravenous buprenorphine in conscious horses. — Love EJ, Pelligand L, Taylor PM, Murrell JC, Sear JW Veterinary anaesthesia and analgesia (2015)
[46]
Evaluation of thermal antinociceptive effects after intramuscular administration of buprenorphine hydrochloride to American kestrels (Falco sparverius). — Ceulemans SM, Guzman DS, Olsen GH, Beaufrère H, Paul-Murphy JR American journal of veterinary research (2014)
[47]
Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. — Cote J, Montgomery L Pain medicine (Malden, Mass.) (2014)
[48]
Analysis of buprenorphine in whole blood using liquid chromatography-tandem mass spectrometry. — Stephenson JB Journal of analytical toxicology (2013)
[49]
Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs. — Niyom S, Mama KR, De Rezende ML American journal of veterinary research (2012)
[50]
Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine. — Upadhyay J, Anderson J, Baumgartner R, Coimbra A, Schwarz AJ, Pendse G et al. NeuroImage (2012)
[51]
Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. — Papoutsis II, Nikolaou PD, Athanaselis SA, Pistos CM, Spiliopoulou CA, Maravelias CP Journal of pharmaceutical and biomedical analysis (2011)
[52]
Issues pertaining to the analysis of buprenorphine and its metabolites by gas chromatography-mass spectrometry. — Wang YS, Lin DL, Yang SC, Wu MY, Liu RH, Su LW et al. Journal of chromatography. A (2010)
[53]
Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. — Chang Y, Moody DE Drug metabolism letters (2009)
[54]
A simple gas chromatography-mass spectrometry procedure for the simultaneous determination of buprenorphine and norbuprenorphine in human urine. — Fuller DC Journal of analytical toxicology (2008)
[55]
Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats. — Pirnay SO, Mégarbane B, Borron SW, Risède P, Monier C, Ricordel I et al. Basic & clinical pharmacology & toxicology (2008)
[56]
High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. — Barutell C, Camba A, González-Escalada JR, Rodríguez M Pain practice : the official journal of World Institute of Pain (2008)
[57]
The effects of buprenorphine on behaviour in the ACI and BN rat inbred strains. — Avsaroglu H, Sommer R, Hellebrekers LJ, van Zutphen LF, van Lith HA Laboratory animals (2008)
[58]
Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. — Hegstad S, Khiabani HZ, Øiestad EL, Berg T, Christophersen AS Journal of analytical toxicology (2007)
[59]
Use of a transdermal matrix patch of buprenorphine in cats: preliminary pharmacokinetic and pharmacodynamic data. — Murrell JC, Robertson SA, Taylor PM, McCown JL, Bloomfield M, Sear JW The Veterinary record (2007)
[60]
Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. — Jensen ML, Foster D, Upton R, Grant C, Martinez A, Somogyi A Xenobiotica; the fate of foreign compounds in biological systems (2007)
[61]
Effects of buprenorphine on nociception and spontaneous locomotor activity in horses. — Carregaro AB, Luna SP, Mataqueiro MI, de Queiroz-Neto A American journal of veterinary research (2007)
[62]
Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies. — Louis F International journal of clinical practice (2006)
[63]
The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. — Sorge RE, Stewart J Psychopharmacology (2006)
[64]
Pharmacokinetics of buprenorphine after intravenous administration in the mouse. — Yu S, Zhang X, Sun Y, Peng Y, Johnson J, Mandrell T et al. Journal of the American Association for Laboratory Animal Science : JAALAS (2006)
[65]
Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. — Liu KS, Tzeng JI, Chen YW, Huang KL, Kuei CH, Wang JJ Anesthesia and analgesia (2006)
[66]
Potentials of ion trap collisional spectrometry for liquid chromatography/electrospray ionization tandem mass spectrometry determination of buprenorphine and nor-buprenorphine in urine, blood and hair samples. — Favretto D, Frison G, Vogliardi S, Ferrara SD Rapid communications in mass spectrometry : RCM (2006)
[67]
Buprenorphine in cancer pain. — Davis MP Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2005)
[68]
Liquid chromatography-mass spectrometric analysis of buprenorphine and its N-dealkylated metabolite norbuprenorphine in rat brain tissue and plasma. — Yue H, Borenstein MR, Jansen SA, Raffa RB Journal of pharmacological and toxicological methods (2005)
[69]
Buprenorphine: considerations for pain management. — Johnson RE, Fudala PJ, Payne R Journal of pain and symptom management (2005)
[70]
In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. — Picard N, Cresteil T, Djebli N, Marquet P Drug metabolism and disposition: the biological fate of chemicals (2005)
[71]
Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. — Christoph T, Kögel B, Schiene K, Méen M, De Vry J, Friderichs E European journal of pharmacology (2005)
[72]
The antinociceptive effect of buprenorphine and its long-acting ester buprenorphine benzoate in rats. — Yang C, Lan KM, Liu KS, Chen YW, Tzeng JI, Ho ST et al. Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists (2004)
[73]
Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. — Pirnay S, Bouchonnet S, Hervé F, Libong D, Milan N, D'Athis P et al. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2004)
[74]
Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. — Ide S, Minami M, Satoh M, Uhl GR, Sora I, Ikeda K Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2004)
[75]
Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. — Tzschentke TM Psychopharmacology (2004)
[76]
Transdermal buprenorphine. — Evans HC, Easthope SE Drugs (2003)
[77]
Aromatase is the major enzyme metabolizing buprenorphine in human placenta. — Deshmukh SV, Nanovskaya TN, Ahmed MS The Journal of pharmacology and experimental therapeutics (2003)
[78]
Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. — Sittl R, Griessinger N, Likar R Clinical therapeutics (2003)
[79]
Effects of buprenorphine on candy and sweetened fluid self-administration by rhesus monkeys. — Comer SD, Evans SM, Pudiak CM, Foltin RW Psychopharmacology (2002)
[80]
Buprenorphine: a reappraisal of its antinociceptive effects and therapeutic use in alleviating post-operative pain in animals. — Roughan JV, Flecknell PA Laboratory animals (2002)
[81]
Antinociceptive activity of a novel buprenorphine analogue. — Lattanzi R, Negri L, Schmidhammer H, Giannini E Life sciences (2002)
[82]
Buprenorphine treatment of patients with non-malignant musculoskeletal diseases. — Balint G Clinical rheumatology (2002)
[83]
Buprenorphine in a transdermal therapeutic system--a new option. — Böhme K Clinical rheumatology (2002)
[84]
Characterization of the discriminative stimulus effects of buprenorphine in pigeons. — Galici R, Brandt MR, France CP Psychopharmacology (2002)
[85]
Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. — Polettini A, Huestis MA Journal of chromatography. B, Biomedical sciences and applications (2001)
[86]
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. — Huang P, Kehner GB, Cowan A, Liu-Chen LY The Journal of pharmacology and experimental therapeutics (2001)
[87]
Fatal intoxication following self-administration of a massive dose of buprenorphine. — Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G Journal of forensic sciences (2000)
[88]
Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. — Schuh KJ, Johanson CE Drug and alcohol dependence (1999)
[89]
Interactions of buprenorphine and selective dopamine receptor antagonists in the rat nucleus accumbens. — Nantwi KD, Hicks S, Bradley D, Schoener EP General pharmacology (1998)
[90]
In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. — Iribarne C, Picart D, Dréano Y, Berthou F Fundamental & clinical pharmacology (1998)
[91]
Mutagenesis of the mouse delta opioid receptor converts (-)-buprenorphine from a partial agonist to an antagonist. — Bot G, Blake AD, Li S, Reisine T The Journal of pharmacology and experimental therapeutics (1998)
[92]
Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine. — Everhart ET, Cheung P, Shwonek P, Zabel K, Tisdale EC, Jacob P et al. Clinical chemistry (1997)
[93]
HPLC/MS determination of buprenorphine and norbuprenorphine in biological fluids and hair samples. — Tracqui A, Kintz P, Mangin P Journal of forensic sciences (1997)
[94]
Sublingual buprenorphine compared to morphine delivered by a patient-controlled analgesia system as postoperative analgesia after prostatectomy. — Gaitini L, Moskovitz B, Katz E, Vaisberg A, Vaida S, Nativ O Urologia internationalis (1996)
[95]
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. — Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD Journal of analytical toxicology (1996)
[96]
A simple thin-layer chromatographic method for the analysis of buprenorphine in urine. — Alemany G, Gamundí A, Rosselló C, Nicolau MC Biomedical chromatography : BMC (1996)
[97]
Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. — Kamei J, Saitoh A, Suzuki T, Misawa M, Nagase H, Kasuya Y Life sciences (1995)
[98]
Effects of morphine, buprenorphine, pentazocine and nalorphine on acquisition and extinction of active avoidance responses in rats. — Saha N, Datta H, Sharma PL Indian journal of physiology and pharmacology (1990)
[99]
Low dose naloxone enhances buprenorphine in a tooth pulp antinociceptive assay. — Bergman SA, Wynn RL, Myers DE, Rudo FG Archives internationales de pharmacodynamie et de therapie (1988)
[100]
Tolerance to the effects of buprenorphine on schedule-controlled behavior and analgesia in rats. — Berthold CW, Moerschbaecher JM Pharmacology, biochemistry, and behavior (1988)